The market is growing rapidly and expanding due to increasing focus on precision medicine and the development of innovative therapies for cancer, neurology, and rare diseases. Growing advancements in PROTACs and molecular glue technologies, along with rising biopharmaceutical investments, are further driving global market growth.
The U.S. targeted protein degradation is an advanced therapeutic approach that selectively removes harmful or disease-causing proteins from cells using technologies such as PROTACs and molecular glues to treat cancer and other chronic diseases. The U.S. targeted protein degradation market is growing due to increasing demand for precision medicine and advanced therapies for cancer, neurological, and autoimmune diseases. Strong presence of leading biotechnology and pharmaceutical companies, rising clinical trial activities, and growing investments in PROTAC and molecular glue technologies are accelerating innovation. Additionally, advanced healthcare infrastructure, programs, and research funding, and expanding drug discovery programs are further contributing to market growth across the country.
The global targeted protein degradation therapy market size was estimated at USD 3.2 billion in 2025 and is predicted to increase from USD 3.94 billion in 2026 to approximately USD 25.36 billion by 2035, expanding at a CAGR of 23% from 2026 to 2035.
The future outlook of the U.S. targeted protein degradation market remains highly positive due to rising clinical advancements, increasing adoption of precision medicine, and expanding applications in oncology and neurological disorders. Growing investments in PROTAC and molecular glut technologies, along with strong biotechnology research activities, are expected to accelerate innovation and long-term market growth across the country.
| Parameter | Data |
| Active TPO Clinical Trials in the U.S. | 150+ trials |
| PROTAC Drug Candidates | 40+ candidares |
| FDA Drug Approvals | 55 approvals |
| Annual U.S. Cancer Cases | 2 Million cases |
| NIH Cancer Research Funding | UDA 7+ Billion |
| Oncology=Focused TDP Pipeline | 70% + |
The U.S. targeted protein degradation market is growing due to rising cancer research, increasing clinical trial activities, and strong investments in innovative therapies such as PROTACs and molecular glues. Expanding biotechnology research and supportive healthcare infrastructure are further accelerating drug development and market expansion across the country.
The proteolysis targeting chimeras (PROTACs) segment dominated the U.S. targeted protein degradation market with 55% share in 2025 due to its strong ability to selectively disease degrade-causing protein that are difficult to target with traditional therapies. Increasing clinical success in oncology research, rising pharmaceutical investments, and expanding development of precision medicine further supported segment growth. Additionally, PROTACs offer improved therapeutic effectiveness, broader disease application, and reduced drug resistance, strengthening their adoption across the healthcare sector.
The cancer segment led the U.S. targeted protein degradation market with a share of 40% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to the increasing global burden of cancer and growing demand for highly targeted treatment approaches. Technologies such as PROTACs and molecular glues are widely used to eliminate cancer-driving proteins that conventional therapies cannot effectively target. Rising oncology research, expanding clinical trials, and strong pharmaceutical investments in precision cancer therapies further strengthened the segment’s market leadership.
The small molecules segment held a dominant share of 60% in 2025 due to their superior ability to penetrate cells, ease of administration, and cost-effective manufacturing. They are widely used in PROTAC and molecular glue development for treating cancer and neurological disorders. Increasing clinical research activities, strong pharmacokinetic properties, and growing pharmaceutical investments further supported the segment’s dominance in the global healthcare industry.
The therapeutic applications segment dominated the U.S. targeted protein degradation market with a share of 75% in 2025 due to the rising use of advanced degradation technologies in treating cancer, neurological, autoimmune, and rare diseases. Increasing demand for precision medicine, strong clinical success of PROTAC and molecular glue therapies, and growing pharmaceutical R&D investments further supported segment growth. Expanding focus on effective disease treatment solutions strengthened its leading position in the market.
Leading companies in the U.S. market include Arvinas, Kymera Therapeutics, C4 Therapeutics, and Nurix Therapeutics. These players are driving market growth through advanced PROTAC and molecular glue platforms, strong oncology and immunology pipelines, and continuous innovation in “undruggable” protein targeting. Increasing clinical trials and expanding R&D investments in precision medicine further strengthen their position in the U.S. targeted protein degradation landscape.
By Technology
By Target Disease
By Drug Class
By Application
